about
Relation of systolic blood pressure to survival in both ischemic and nonischemic systolic heart failure.Cyclin A2 induces cardiac regeneration after myocardial infarction through cytokinesis of adult cardiomyocytes.Myocardial regeneration therapy for ischemic cardiomyopathy with cyclin A2.Long-term outcomes of heart transplantation recipients with transplant coronary artery disease who develop in-stent restenosis after percutaneous coronary intervention.Obesity in heart failure: impact on survival and treatment modalities.Molecular basis of recovering on mechanical circulatory support.Outcomes of biventricular mechanical support patients discharged to home to await heart transplantation.Late Surgical Bleeding Following Total Artificial Heart Implantation.Systematic donor selection review process improves cardiac transplant volumes and outcomes.Agreement between risk and priority for heart transplant: Effects of the geographic allocation rule and status assignment.Periportal fibrosis without cirrhosis does not affect outcomes after continuous flow ventricular assist device implantation.Comparison of sirolimus-, paclitaxel-, and everolimus-eluting stent in unprotected left main coronary artery percutaneous coronary intervention.Radiation coronary arteritis refractory to surgical and percutaneous revascularization culminating in orthotopic heart transplantation.Risk stratification in patients with advanced heart failure requiring biventricular assist device support as a bridge to cardiac transplantation.Association between preoperative peripheral blood mononuclear cell gene expression profiles, early postoperative organ function recovery potential and long-term survival in advanced heart failure patients undergoing mechanical circulatory support.Percutaneous angioplasty of stenotic outflow graft anastomosis of HeartMate II.Survival After Heart Transplantation in Patients With Arrhythmogenic Right Ventricular Cardiomyopathy.Multicenter international registry of unprotected left main coronary artery percutaneous coronary intervention with everolimus-eluting stents.Adverse Effects of Delayed Transplant Listing among Patients with Implantable Left Ventricular Assist Devices.Pulmonary function tests do not predict mortality in patients undergoing continuous-flow left ventricular assist device implantation.Small Left Ventricular Size Is an Independent Risk Factor for Ventricular Assist Device Thrombosis.Developing and implementing a heart failure data mart for research and quality improvement.Cyclin A2 induces cardiac regeneration after myocardial infarction and prevents heart failure.Effect of regional competition on heart transplant waiting list outcomesInvasive Hemodynamics and Rejection Rates in Patients With Cardiac Sarcoidosis After Heart TransplantationCardiac sarcoidosis: Diagnosis confirmation by bronchoalveolar lavage and lung biopsyEditorial commentary: Searching for the sweet spot of cardioprotection in cancer treatment related cardiotoxicity: Who will benefit?Rivaroxaban With or Without Aspirin in Patients With Heart Failure and Chronic Coronary or Peripheral Artery DiseaseCardiovascular Disease and Cancer: Is There Increasing Overlap?COVID-19 and acute myocardial injury: the heart of the matter or an innocent bystander?Cardiovascular disease and COVID-19: implications for prevention, surveillance and treatment
P50
Q33793731-010D52EE-9EF8-46E5-908A-80DD6BAC8DCDQ34405482-96F0B541-6A2A-499C-9E5C-CC2562C02550Q34611892-5B7115FE-4C1D-48A9-AFF4-5AB9F7CEAF41Q37491997-CAF7FECD-CEF3-4BA8-A2B1-0C808978096AQ38128922-E27BCF93-8D4F-4DF9-810D-192EC3C84848Q38164908-F0DCB01A-316E-44DF-B0D8-D6C996E57F20Q38217929-0210214C-5D96-4C9D-9EDB-99AE9BF51395Q38569304-4D0C2B61-559D-48D8-9A11-AFE74B477B29Q38597280-83062FC1-31CE-4E0A-8296-3CFCEECFE4DCQ38993725-6F9296D5-D830-4B72-A6CA-3FE99A6ACAFDQ41285907-6F0A5425-E7DA-4A11-831D-02A7A2B08DA1Q41872107-EA9F5824-8D5E-43A7-9EE3-792DB177E62DQ43716125-9D58EEA8-DF16-488F-B99C-AB08CEDF552BQ46017771-B8EA27FD-0DD1-4211-A32C-212483AC6D93Q46129739-9B217681-ECEF-49DB-BAA0-79280FFBB04CQ46308876-BD1E9913-3253-41E5-8957-AF33D7EDBABAQ46675488-71AEBA40-0706-4915-8961-E18EDD0FC8B5Q47399763-DC24DFFB-039A-4DD1-A4D6-F605DFD5ACCEQ48498289-FDF23146-A316-4A02-B45C-3A4122F11C76Q50868919-327B5E2C-999D-4E17-A5AB-01CDA07CFD99Q52314323-6EEECBD2-4DC5-4451-9052-64EF5DB74131Q52578113-A5984850-19BD-4881-873B-219AE22AB8F3Q53553910-B5CD5180-364F-4585-85AD-81AE5FAE449FQ89296543-315A4C54-4A0C-4BF4-8025-58308B9B5CA1Q90513452-D8961C47-555D-4727-AEDF-0CF6F72DDC39Q91698059-8DC45D73-118B-4F00-8119-A307D86C3A9DQ91855414-87EDCCCA-CAA7-426D-B6FD-E229712551FAQ92520984-BD277630-7C3A-4D2E-AC92-31B745A05AB9Q92898995-9C94CCFD-B4C8-4053-942F-A219E5F37D3BQ94473124-F7D4C3B6-F180-4B54-A1E6-DD0D1AE69A52Q95831343-83291940-9407-4E44-BFDA-A1AB45E4EA98
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Richard K Cheng
@ast
Richard K Cheng
@en
Richard K Cheng
@es
Richard K Cheng
@nl
type
label
Richard K Cheng
@ast
Richard K Cheng
@en
Richard K Cheng
@es
Richard K Cheng
@nl
prefLabel
Richard K Cheng
@ast
Richard K Cheng
@en
Richard K Cheng
@es
Richard K Cheng
@nl
P106
P31
P496
0000-0001-5994-5998